Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2019-11-27 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd., a foreign private issuer. It reports the third quarter 2019 financial results, including detailed financial data such as cash balances, expenses, operating loss, and net loss for the nine months ended September 30, 2019. The document contains consolidated statements of financial position and comprehensive income, which are substantive financial data for an interim period shorter than a full fiscal year. The presence of detailed financial statements and analysis for a quarterly period aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a certification but contains actual financial results and analysis. Therefore, the appropriate classification is IR with high confidence.
2019-11-27 English
Immediate Report
Board/Management Information Classification · 98% confidence The document is explicitly titled "Form 6-K" and is filed by a "Foreign Private Issuer" with the SEC. Form 6-K is used to report material events that occur between the filing of annual reports (Form 20-F). The content details the resignation of a director and the intended appointment of a replacement. This type of announcement regarding changes in senior management or the board of directors directly corresponds to the definition of Board/Management Information (MANG). Although Form 6-K is a general SEC filing, the specific subject matter (director resignation/appointment) makes MANG the most accurate classification over the general fallback RNS.
2019-10-31 English
Immediate Report
Board/Management Information Classification · 98% confidence The document explicitly states the subject matter: 'Resignation of Mr. Oded Nagar, a non-executive and external director of the Company.' This directly relates to changes in the board of directors or senior management. The filing is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (1948 chars) and it announces the change, referencing an attached PDF, but the core content is the management change itself, making MANG the most specific fit over a general RPA or RNS.
2019-10-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. The content specifically announces the resignation of a non-executive director and the intended appointment of a new member to the Audit and Compensation Committees. This is an announcement related to changes in the company's board of directors. The document length is short (1861 characters) and contains no financial data or detailed reports, so it is not an Annual Report or Management Report. It fits the category of Board/Management Information (MANG) as it concerns changes in the board and senior management positions.
2019-10-31 English
Immediate Report
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. It contains the company's financial results for the first half of 2019, including consolidated statements of financial position and comprehensive income. While it is filed as a 6-K, the content is a comprehensive interim financial report for a period shorter than a full fiscal year (six months ended June 30, 2019) and includes substantive financial data and analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2019
2019-09-04 English
Immediate Report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is an 'Immediate Report' under Israeli regulations concerning a 'Foreign Corporation' and references the 'Israel Securities Authority' and 'Tel Aviv Stock Exchange'. Crucially, the text states: "Attached hereto is a report on*Financial results for the quarter ended June 30, 2019*" followed by a PDF filename. Since the document itself is short (1894 chars) and serves only to announce the publication of the actual financial results report (which is attached/linked), it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. The content relates to quarterly financial results, but this specific filing is the announcement vehicle.
2019-09-04 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.